



ERASMUS MC BIOMEDICAL FUND CO-LEADS SERIES A FINANCING ROUND OF SKYLINE DIAGNOSTICS

Rotterdam, October 5, 2007- The Erasmus MC Biomedical Fund announced today the closure of the Series A financing round of Skyline Diagnostics B.V. The round was co-led by Life Sciences Partners.

Skyline Diagnostics is a spin-off company from the Erasmus University Medical Center in Rotterdam. The company develops and commercializes diagnostic tools for cancer using microarray technology. The diagnostic device furnishes a genomic fingerprint of the tumor that permits a precise diagnosis and a predictive assessment of the individual's prognosis. The company currently has three products in its development pipeline: biochips for acute myeloid leukemia, brain tumors and myeloma (Kahler's disease).

Dr. Henk Viëtor, CEO at Skyline Diagnostics: "We very pleased to have two experienced venture capital investors like the Erasmus MC Biomedical Fund and LSP investing in our company. This will enable Skyline to fulfill its ambitions to take the next essential steps in bringing its first product, the AML Biochip, to the market. Acute myeloid leukemia (AML) is the most common form of leukemia. This product will provide clinicians new insights in the prognosis and course of the disease."

"We are excited to be making this investment in Skyline Diagnostics, which we believe is one of the most promising companies in its field today" says Tom Schwarz, partner at the Erasmus MC Biomedical Fund. "The combination of world class science, experienced management and strong financial backing will allow the company to successfully develop and market its diagnostic products. I am personally looking forward to working closely with the management team as a new member of the company's Supervisory Board."

Dr. John de Koning, investment manager at LSP and member of Skyline Diagnostics' Supervisory Board: "Skyline Diagnostics is a frontrunner in implementing microarray diagnostics in clinical practice. Building on the company's expertise and broad scientific and clinical network, we expect Skyline Diagnostics to be in an excellent position to successfully bring its products to the market, creating long-term value. We are delighted to be able to support the Company and its management team in attaining this goal."

About Skyline Diagnostics (www.skyline-diagnostics.nl)

Skyline Diagnostics develops and commercializes diagnostic products for cancer using gene expression profiling. This technology enables scientists to study the activity of nearly the complete human genome in one single experiment and can provide the clinician new insight in the development and prognosis of disease and the response to

treatment. The company collaborates closely with several departments of the Erasmus MC to ensure disease expertise and new diagnostic signatures. Skyline was founded in 2005 by the inventors (Departments of Hematology and Bio-informatics) of the gene expression profile for AML (including Prof. dr. B. Löwenberg, CSO of the company) and dr. Henk Viëtor (CEO). Skyline has close collaborations with several academic and industrial partners including Affymetrix (Santa Clara, USA) and holds a Powered by Affymetrix™ (PbA) licensing deal for several cancer indications. In 2007, Skyline received the BioBusiness “Start-up of the Year Award”. The company aims to launch the first product (the AML Biochip) in 2008.

About the Erasmus MC Biomedical Fund (www.erasmusmcfund.nl)

The Erasmus MC Biomedical Fund is an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Rotterdam region. The fund targets companies that are developing commercially promising products and technologies in life sciences, including pharmaceuticals, biotechnology, information technology and other high technology opportunities that offer venture capital returns.

About LSP (www.lspvc.com)

LSP (Life Sciences Partners) is a leading independent European venture capital firm, providing private equity financing to early- to mid-stage life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With EUR 400 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors.

For further information please contact:

Tom Schwarz

Tel: + 31 (0) 6 53279243

E-mail: tschwarz@erasmusmcfund.nl